Therefore, the propensity of the malignancy to mutate is critically important for the risk of relapse. Although there is a slower pace of relapse for CML, the general pace of relapse remains very ...

AXS-05 was well-tolerated and significantly delayed the time to agitation relapse compared with placebo in patients with Alzheimer’s disease, according to phase 3 data from the ACCORD-2 trial.